Linde Healthcare Continues to Support Innovation in Advanced Respiratory Care

Linde Healthcare, a global business of The Linde Group, has announced the new beneficiaries of its REALfund initiative, a programme supporting ideas and projects with the potential to improve patient outcomes and health economics across the wide field of respiratory medicine.

Selected from many high quality applications from leading clinics and research organisations around the world, three grantees of the REALfund will receive funds to support their innovative research:

  • PD Johannes Bickenbach MD and Professor Michael Dreher MD, University Hospital Aachen, Germany, will investigate if exacerbations of invasively mechanically ventilated COPD patients can be predicted by an algorithm based on software analysis of data which will be read out from the ventilator.
  • Thomas Bitter MD, Heart and Diabetes Centre Bad Oeynhausen, Germany, will study if high flow oxygen therapy could serve as a new therapeutic approach to treat patients suffering from Cheyne-Stokes respiration associated with Chronic Heart Failure.
  • Professor Christopher H. Fanta MD, Brigham and Women’s hospital, Harvard Medical School, Boston, USA, plans to develop a smartphone app which is able to alert COPD patients about deterioration in their breathing and to provide recommendations for patient-initiated first actions to prevent serious exacerbations of their conditions.

Dr Christian Wojczewski, Head of Linde Healthcare states: "Linde Healthcare continues to be committed to co-operating with researchers from around the world to support research and innovative developments in the area of respiratory medicine. The newly awarded REALfund grants fit very well into Linde Healthcare's footprint as global healthcare organisation specialising along an integrated respiratory care path. The work of these researchers, when realised, will help healthcare professionals, support healthcare systems and further improve the quality of care and life for patients."

Grantees of the REALfund are selected with the help of medical and scientific experts and will be supported in their continued research. Dr Konstantin Fiedler, Head of Innovation at Linde Healthcare states: "The aim of Linde Healthcare’s REALfund initiative is to seek and reward ideas that have real potential to be developed into better respiratory care solutions for patients. We are proud of having received many high-quality applications from different regions around the world. We commend all applicants to the fund for their commitment to innovation and idea development in this area of healthcare. The grantees saw the potential in their projects and we at Linde Healthcare are delighted to recognise and reward the ideas that will truly benefit patients."

For further information about the REALfund, please visit:
http://www.linde-realfund.com

About Linde Healthcare
Linde Healthcare is a global leader specialising along an integrated respiratory care path. It combines pharmaceutical gases, medical devices, services and clinical care into solutions with the patient in mind. Its products and services make a difference in the lives of its patients and to its healthcare partners in the care continuum from hospital to home. A global business unit of The Linde Group, it is present in over 60 countries and generated revenues of EUR 3.059 bn in 2014 and employs 16,643 employees.

About The Linde Group
In the 2014 financial year, The Linde Group generated revenue of EUR 17.047 bn, making it the largest gases and engineering company in the world with approximately 65,500 employees working in more than 100 countries worldwide. The strategy of The Linde Group is geared towards long-term, profitable growth and focuses on the expansion of its international business with forward-looking products and services. Linde acts responsibly towards its shareholders, business partners, employees, society and the environment - in every one of its business areas, regions and locations across the globe. The company is committed to technologies and products that unite the goals of customer value and sustainable development.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...